Metagenomic NGS for Diagnosis of Pneumonia

Pneumonia Clinical Trial

Official title:

Impact of Incorporating Metagenomic Next-generation Sequencing in the Management of Pneumonia on Diagnostic Efficiency and Outcomes: A Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05979350
• Other study ID #: 202305104RINB
• Status: Not yet recruiting
• Phase: N/A
• Start date: August 1, 2023
• Est. completion date: July 31, 2025

Study information

• Verified date: July 2023
• Source: National Taiwan University Hospital
• Contact: Sheng-Yuan Ruan, MD
• Phone: 886-2-23123456
• Email: syruan[@]ntu.edu.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this randomized controlled trial, we aim to evaluate the efficacy of incorporating mNGS in the management of pneumonia on efficiency and accuracy of causative pathogen identification, proportion of participants with effective antimicrobial therapy, length of hospitalization, and mortality.

Description:

This is an open-label, randomized, multi-center, phase 2 study that will evaluate the efficacy of incorporating mNGS in the management of severe pneumonia on accuracy and efficiency of achieving definite diagnosis of identifying causative pathogens of pneumonia, appropriate antimicrobial therapy and patient outcomes. The diagnosis of pneumonia requires radiological evidence of pneumonia and at least two of the following clinical criteria: new, or worsening cough, new or worsening expectoration of sputum, new or worsening dyspnea, hemoptysis, pleuritic chest pain, and fever (≥38.0°C). Severe pneumonia is defined as pneumonia with hypoxemia requiring orotracheal intubation and mechanical ventilation support. Written informed consent is needed from the eligible subjects or from their legal guardian at the time of recruitment. After completing informed consent, subjects will be randomized with a 1:1 allocation ratio via a web-based randomization system to receive standard of care (SOC) using culture and serology based work-up for pathogen detection or SOC with additional mNGS method using APGseq ® (Asia Pathogenomics, New Taipei City, Taiwan) for pathogen detection. The treatment for pneumonia is suggested following the Taiwan Guidelines for the Management of Pneumonia published in 2018. After randomization, the subjects will be followed until death, discharged from the hospital or 28 days after randomization whichever comes first. The total study duration is expected to be two years from the first subject enrolled to the final analysis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: July 31, 2025
• Est. primary completion date: May 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Presenting to the ICU with a diagnosis of pneumonia (fulfilled with both radiographic and clinical criteria)

2. Adults aged =18 years

3. Orotracheally intubated

4. ICU admission for <24 hours

5. APACHE II score <35 on ICU admission

Exclusion Criteria:

1. Life expectancy below 4 weeks

2. With an existing directive to withhold life-sustaining treatment

3. Patients not willing or able to provide a lower respiratory tract sample at ICU admission

4. Previous work-up has identified specific pathogens which can account for the index event of pneumonia

5. Multiplex PCR or NGS testing has been done for pathogen detection before screening

Related Conditions & MeSH terms

• Diagnosis
• Disease
• Pneumonia

Intervention

Diagnostic Test:
• Metagenomic next-generation sequencing
Metagenomic NGS testing for pathogen identification will be done for airway and blood specimens using APGseq ® (Asia Pathogenomics, New Taipei City, Taiwan). The sample preparation for mNGS testing was as follows: 5-10 mL of whole blood were centrifuged at 1,600g for 10 min at 4°C to separate the plasma. Plasma samples were transferred to 2 mL sterile tubes for the following DNA or RNA extraction. In general, 300ul of plasma sample was used for DNA extraction. Total genomic DNA from samples were extracted using the column-based method (e.g. QIAamp DNA Microbiome Kit, Qiagen for DNA extraction; or QIAamp Viral RNA Mini Kit, Qiagen for RNA extraction, respectively), following the manufacturer's operational manual. The RNA was reverse transcribed and synthesized to double-stranded complementary DNA (ds cDNA) with SuperScript II Reverse Transcription Kit (Invitrogen).
• Standard work-up for pneumonia
Endotracheal aspirates, blood samples, urine samples, and nasopharyngeal swabs were obtained from the patients as soon as possible after ICU admission. Bacterial culture was performed, with the use of standard techniques, on blood samples and endotracheal aspirates. Urine antigen detection was performed for detection of L. pneumophila and S. pneumoniae. A PCR assay was performed on nasopharyngeal swabs for the detection of influenza A and B viruses and SARS-CoV-2 viruses. Fungal or mycobacterial detections, and whether to use multiplex PCR for pathogen detection, such as the FilmArray system, were determined at the discretion of the physicians.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
National Taiwan University Hospital	Far Eastern Memorial Hospital, National Taiwan University Hospital Hsin-Chu Branch

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to achieving definite diagnosis in modified intention-to-treat (mITT) analysis.	Cumulative probability of achieving definite diagnosis in terms of accurately identifying causative pathogens of pneumonia, estimated by the Kaplan-Meier method in a time frame of 7 days in modified intention-to-treat (mITT) analysis.	7 days
Secondary	Time to achieving definite diagnosis in intention-to-treat analysis.	To test the robustness of mITT analysis for the primary study endpoint as compared with standard ITT analysis. (Sensitivity analysis)	7 days
Secondary	Pathogen detection rate between two groups by the 72th hour.	Proportion of participants with accurate diagnosis for the causative pathogens of pneumonia by the 72th hour after randomization in mITT analysis.	72 hours
Secondary	Pathogen detection rate between two groups by the end of study.	Proportion of participants with accurate diagnosis for the causative pathogens of pneumonia by the day 28 after randomization in mITT analysis.	28 days
Secondary	Impact of mNGS on appropriate antibiotic prescription.	Proportion of participants on effective antimicrobial therapy by the 72th hour after randomization in mITT analysis.	72 hours
Secondary	28-day mortality in mITT analysis.	Kaplan-Meier curves of 28-day survival using mITT cohort. Log-rank tests are used to test statistical significance.	28 days
Secondary	28-day mortality in ITT analysis (total cohort).	Kaplan-Meier curves of 28-day survival using total cohort. Log-rank tests are used to test statistical significance.	28 days
Secondary	Impact of mNGS on respiratory and mortality outcome.	Kaplan-Meier curves of ventilator-free survival in 28 days after randomization using mITT cohort. Log-rank tests are used to test statistical significance.	28 days
Secondary	Impact of mNGS on the length of ICU stay	Curves of alive ICU discharge in 28 days after randomization using the Fine-Gray model. Death will treated as a competing risk.	ICU discharge or 28 days